Literature DB >> 23107866

Systemic fungal infections in patients with human inmunodeficiency virus.

C Rodríguez-Cerdeira1, R Arenas2, G Moreno-Coutiño2, E Vásquez2, R Fernández2, P Chang3.   

Abstract

Histoplasmosis is a systemic infection caused by the dimorphic fungus Histoplasma capsulatum. In immunocompromised patients, primary pulmonary infection can spread to the skin and meninges. Clinical manifestations appear in patients with a CD4(+) lymphocyte count of less than 150 cells/μL. Coccidioidomycosis is a systemic mycosis caused by Coccidioides immitis and Coccidioides posadasii. It can present as diffuse pulmonary disease or as a disseminated form primarily affecting the central nervous system, the bones, and the skin. Cryptococcosis is caused by Cryptococcus neoformans (var. neoformans and var. grubii) and Cryptococcus gattii, which are members of the Cryptococcus species complex and have 5 serotypes: A, B, C, D, and AD. It is a common opportunistic infection in patients with human immunodeficiency virus (HIV)/AIDS, even those receiving antiretroviral therapy. Histopathologic examination and culture of samples from any suspicious lesions are essential for the correct diagnosis of systemic fungal infections in patients with HIV/AIDS.
Copyright © 2011 Elsevier España, S.L. and AEDV. All rights reserved.

Entities:  

Keywords:  Adquired inmunodeficiency syndrome; Coccidioidomicosis; Coccidioidomycosis; Criptococosis; Cryptococcosis; Histoplasmosis; Human immunodeficiency virus; Sida; Virus de la inmunodeficiencia humana

Mesh:

Year:  2012        PMID: 23107866     DOI: 10.1016/j.ad.2012.06.017

Source DB:  PubMed          Journal:  Actas Dermosifiliogr        ISSN: 0001-7310


  5 in total

1.  Disseminated histoplasmosis in an HIV patient with CD4 count of 1 cell/µL.

Authors:  Sri Harsha Tella; Ahmed Abuzaid
Journal:  BMJ Case Rep       Date:  2014-08-19

2.  Differential Diagnosis of Fungal Pneumonias vs. Tuberculosis in AIDS Patients by Using Two New Molecular Methods.

Authors:  Leticia Bernal-Martínez; Laura Herrera; Clara Valero; Paula de la Cruz; Larisa Ghimpu; Ana C Mesa-Arango; Gabriela Santoni; Lidia Goterris; Rosario Millán; María José Buitrago
Journal:  J Fungi (Basel)       Date:  2021-04-27

3.  In Vitro Activity of a Novel Antifungal Compound, MYC-053, against Clinically Significant Antifungal-Resistant Strains of Candida glabrata, Candida auris, Cryptococcus neoformans, and Pneumocystis spp.

Authors:  G Tetz; M Collins; D Vikina; V Tetz
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

4.  The HIF-1α/LC3-II Axis Impacts Fungal Immunity in Human Macrophages.

Authors:  Dirk Friedrich; Dorinja Zapf; George S Deepe; Jan Rupp; Björn Lohse; Roger A Fecher
Journal:  Infect Immun       Date:  2019-06-20       Impact factor: 3.441

Review 5.  Therapies and Vaccines Based on Nanoparticles for the Treatment of Systemic Fungal Infections.

Authors:  Brenda Kischkel; Suélen A Rossi; Samuel R Santos; Joshua D Nosanchuk; Luiz R Travassos; Carlos P Taborda
Journal:  Front Cell Infect Microbiol       Date:  2020-09-03       Impact factor: 5.293

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.